Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154376 | 1.00 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL27791880 | 0.86 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL503402 | 0.84 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL6380611 | 0.84 | MEN1 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4442846 | 0.83 | KMT2A (0.60) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8889711 | 0.82 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL5500086 | 0.82 | KMT2A (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20382395 | 0.82 | KMT2A (0.62) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1455608 | 0.82 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL31329448 | 0.82 | CYP1A2 (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10117860-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-11-06 | — | — | US | disclosed |
| EP-3152201-B1 | AMINOESTER DERIVATIVES | CHIESI FARM SPA (IT) | 2018-08-29 | — | — | EP | disclosed |
| US-20170340616-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170340616-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-9763924-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-09-19 | — | — | US | disclosed |
| US-9763924-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-09-19 | — | — | US | disclosed |
| US-9763924-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-09-19 | — | — | US | disclosed |
| EP-3152201-A1 | AMINOESTER DERIVATIVES | Chiesi Farmaceutici S.p.A. (IT) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015185649-A9 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-01-05 | — | — | WO | disclosed |
| WO-2015185649-A9 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-01-05 | — | — | WO | disclosed |
| US-20150352091-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-20150352091-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-20150352091-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| WO-2015185649-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015185649-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | WO | disclosed |
| EP-1078919-B1 | SYNTHESIS OF ALPHA-AMINO-ALPHA',ALPHA'-DIHALOKETONES AND PROCESS FOR THE PREPARATION OF BETA)-AMINO ACID DERIVATIVES BY THE USE OF THE SAME | KANEKA CORP (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-20030158436-A1 | Synthesis of alpha--amino-alpha, alpha'- dihaloketones and process for the preparation of beta--amino acid derivatives by the use of the same | KANEKA CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6573399-B1 | Reacting an alpha -amino acid ester derivative with a base and a dihalomethane | KANEKA CORPORATION (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1078919-A1 | SYNTHESIS OF $g(a)-AMINO-$g(a)',$g(a)'-DIHALOKETONES AND PROCESS FOR THE PREPARATION OF $g(b)-AMINO ACID DERIVATIVES BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158436-A1 | Synthesis of alpha--amino-alpha, alpha'- dihaloketones and process for the preparation of beta--amino acid derivatives by the use of the same | AADAT, BCAT1, AASDHPPT | MEN1 843/4885KMT2A 1205/4885SMN1; SMN2 4483/4885 |
| US-20170340616-A1 | AMINOESTER DERIVATIVES | PDE4A, PDE4B, PDE3A | MEN1 3881/4885KMT2A 1424/4885SMN1; SMN2 4068/4885 |
| US-20150352091-A1 | AMINOESTER DERIVATIVES | PDE4A, PDE4B, PDE3A | MEN1 3881/4885KMT2A 1424/4885SMN1; SMN2 4068/4885 |
| US-10117860-B2 | Aminoester derivatives | PDE4A, PDE4B, PDE3A | MEN1 3881/4885KMT2A 1424/4885SMN1; SMN2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.